Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

UroGen Pharma (URGN) Cash from Investing Activities (2016 - 2025)

Historic Cash from Investing Activities for UroGen Pharma (URGN) over the last 10 years, with Q3 2025 value amounting to $31.4 million.

  • UroGen Pharma's Cash from Investing Activities rose 12941.26% to $31.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $94.5 million, marking a year-over-year increase of 20203.5%. This contributed to the annual value of -$20.6 million for FY2024, which is 206295.91% down from last year.
  • As of Q3 2025, UroGen Pharma's Cash from Investing Activities stood at $31.4 million, which was up 12941.26% from $28.4 million recorded in Q2 2025.
  • UroGen Pharma's Cash from Investing Activities' 5-year high stood at $60.6 million during Q4 2024, with a 5-year trough of -$106.8 million in Q3 2024.
  • For the 5-year period, UroGen Pharma's Cash from Investing Activities averaged around $916000.0, with its median value being $9.1 million (2021).
  • Per our database at Business Quant, UroGen Pharma's Cash from Investing Activities soared by 256357.62% in 2023 and then crashed by 2672094.76% in 2024.
  • Quarter analysis of 5 years shows UroGen Pharma's Cash from Investing Activities stood at $9.1 million in 2021, then soared by 153.24% to $23.1 million in 2022, then plummeted by 149.09% to -$11.3 million in 2023, then soared by 634.39% to $60.6 million in 2024, then plummeted by 48.21% to $31.4 million in 2025.
  • Its last three reported values are $31.4 million in Q3 2025, $28.4 million for Q2 2025, and -$26.0 million during Q1 2025.